Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172179 | 1.00 | KDM4E (0.59) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL2838848 | 1.00 | KDM4E (0.59) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL12418041 | 1.00 | KDM4E (0.59) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4272229 | 1.00 | KDM4E (0.59) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9190252 | 1.00 | KDM4E (0.59) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL5174621 | 0.98 | ALDH1A1 (0.61) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL837391 | 0.98 | ALDH1A1 (0.61) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL851371 | 0.83 | AOC3 (0.62) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL8135905 | 0.83 | AOC3 (0.62) | KDM4ELMNAADRA2AADRA2CHIF1A | |
| SCHEMBL8028471 | 0.82 | AOC3 (0.49) | KDM4ELMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2102169-B1 | INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7408084-B2 | Process for producing optically active β-amino alcohol | KANEKA CORPORATION (JP) | 2008-08-05 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20050277791-A1 | Process for producing optically active beta-amino alcohol | KANEKA CORPORATION (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1512677-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE s-AMINO ALCOHOL | KANEKA CORPORATION (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885LMNA 1618/4885ADRA2A 381/4885 |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | ABCB1, CYP3A43, CYP3A5 | KDM4E 3643/4885LMNA 4605/4885ADRA2A 1185/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885LMNA 1618/4885ADRA2A 381/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885LMNA 1618/4885ADRA2A 381/4885 |
| US-20050277791-A1 | Process for producing optically active beta-amino alcohol | ADH1A, ALDH7A1, ADH1C | KDM4E 1301/4885LMNA 1549/4885ADRA2A 221/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885LMNA 1618/4885ADRA2A 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.